9.77 0.00 (0.00%)
After hours: 4:56PM EST
|Bid||8.75 x 800|
|Ask||10.15 x 4000|
|Day's Range||9.75 - 10.28|
|52 Week Range||7.85 - 19.90|
|Beta (3Y Monthly)||3.46|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Conventional wisdom says insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Iovance Biotherapeutics Inc (NASDAQ: IOVA) saw a director adding to his stake this past week. This San Carlos, California-based clinical-stage biotechnology company focuses on cancer immunotherapy products.
Every investor in Iovance Biotherapeutics Inc (NASDAQ:IOVA) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often Read More...
On a per-share basis, the San Carlos, California-based company said it had a loss of 36 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Nantahala Capital Management is a New Haven-based hedge fund founded in 2004 by 26-year-old Wilmot Harkey. He named his firm after the river in the Smoky Mountains which he visited with his family when he was a kid, as he wanted a name that would remind him of his background. Although, Wil Harkey was very young […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...
Iovance Biotherapeutics stock toppled by double digits Thursday after a third of patients who received its experimental lung cancer regimen worsened following treatment.
Investors need to pay close attention to Lion Biotechnologies (IOVA) stock based on the movements in the options market lately.
The San Carlos, California-based company said it had a loss of 34 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Iovance Biotherapeutics Inc’s (NASDAQ:IOVA): Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicateRead More...
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
RXi reported revenues of $23,000 for the quarter from grants related to BioAxone’s work in spinal cord injury, compared to zero in revenues in 1Q:17. Following the availability of the trial results, RXi will set up data rooms for interested buyers.
The San Carlos, California-based company said it had a loss of 31 cents per share. Losses, adjusted for stock option expense, came to 26 cents per share. The results beat Wall Street expectations. The ...
On a per-share basis, the San Carlos, California-based company said it had a loss of 36 cents. Losses, adjusted for stock option expense, came to 32 cents per share. The results met Wall Street expectations. ...
Lion Biotechnologies (IOVA) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Iovance Biotherapeutics Inc (NASDAQ:IOVA), a $1.45B small-cap, operates in the healthcare industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoing need forRead More...